A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)
Arthritis Research & Therapy · 2024
DOI: 10.1186/s13075-024-03375-w ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Xiaomei Leng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Biosimilar Pharmaceuticals, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) of the phase 3 study. Here we present results for TP2 (study weeks 24–48).
Methods
In this phase 3, multicenter, multiregional, double-blind, active-controlled, equivalence study, participants with active RA despite methotrexate were randomized (1:1:2) to intravenous administration of 8 mg/kg TCZ every 4 weeks to week 48 (TCZ group), or TCZ to week 24 followed by BAT1806/BIIB800 to week 48 (TCZ to BAT1806/BIIB800 group), or BAT1806/BIIB800 to week 48 (BAT1806/BIIB800 group). Efficacy in TP2 was evaluated using American College of Rheumatology (ACR) response criteria (ACR20/50/70) and change from baseline in Disease Activity Score on 28 joints (DAS28). Pharmacokinetics (trough levels), safety, and immunogenicity were also evaluated.
Results
Of 621 randomized participants, 577 (92.9%) completed TP1 and entered TP2 (TCZ: N = 145 [93.5%]; TCZ to BAT1806/BIIB800: N = 142 [92.2%]; BAT1806/BIIB800: N = 290 [92.9%]). Proportions of ACR20 responders were similar between treatment groups throughout TP2 (87.8%, 90.3%, and 90.4%, respectively, at week 48), as were proportions of ACR50 and ACR70 responders, and reduction in DAS28. Drug trough levels and antidrug antibody incidences were comparable between the treatment groups. Adverse events were balanced across the treatment groups and no fatal events were reported.
Conclusion
In TP2, efficacy, safety, immunogenicity, and pharmacokinetic profiles were comparable between the TCZ, TCZ to BAT1806/BIIB800, and BAT1806/BIIB800 groups.
Trial registration
NCT03830203 and EudraCT 2018-002202-31.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.
- Department of Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
- Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2, CM UMK, Bydgoszcz, Poland.
- First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Qilu Hospital of Shandong University, Jinan, China.
- Twoja Przychodnia Centrum Medyczne, Nowa Sól, Poland.
Zitieren
APA
Leng, X., Leszczyński, P., Jeka, S., Liu, S., Liu, H., Miakisz, M., Gu, J., Kilasonia, L., Stanislavchuk, M., Yang, X., Zhou, Y., Dong, Q., Mitroiu, M., Addison, J., Rezk, M. F., & Zeng, X. (2024). A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48). Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03375-w
Vancouver
Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, et al. A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48). Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03375-w
BibTeX
@article{Leng2024,
author = {Leng, Xiaomei and Leszczyński, Piotr and Jeka, Slawomir and Liu, Shengyun and Liu, Huaxiang and Miakisz, Malgorzata and Gu, Jieruo and Kilasonia, Lali and Stanislavchuk, Mykola and Yang, Xiaolei and Zhou, Yinbo and Dong, Qingfeng and Mitroiu, Marian and Addison, Janet and Rezk, Mourad F and Zeng, Xiaofeng},
title = {A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)},
journal = {Arthritis Research & Therapy},
year = {2024},
doi = {10.1186/s13075-024-03375-w}
}
EUVIMED